{"id":"W4402565679","doi":"10.1016/j.annonc.2024.08.2307","title":"LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Radium-223; Asymptomatic; Open label; Prostate cancer; Internal medicine; Oncology; Phases of clinical research; Urology; Randomized controlled trial; Clinical trial; Bone metastasis; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001488416,0.002566,0.003449492,0.0006304312,0.0004847439,0.001412594,0.001492098,0.001740834,0.01021677],"category_scores_gemma":[0.001514443,0.0008835723,0.002216862,0.0005207622,0.001391942,0.001162883,0.0004904886,0.004691899,0.002081327],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001105284,"about_ca_system_score_gemma":0.001920375,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00230549,"about_ca_topic_score_gemma":0.005571861,"domain_scores_codex":[0.9995115,0.0002717192,0.0000193991,0.00008435958,0.00002850362,0.00008455572],"domain_scores_gemma":[0.9991261,0.000223815,0.000150067,0.00005584304,0.00004606065,0.0003980564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.971002,0.006836489,0.0004127811,0.0004038382,0.000970619,0.00003157292,0.00003621216,0.0005319061,0.003014887,0.000138062,0.001729875,0.01489171],"study_design_scores_gemma":[0.9426538,0.05465425,0.0009549122,0.00002275297,0.0003459864,0.00002650052,0.00001592657,0.0003796026,0.0002215486,0.0001132832,0.0005968661,0.00001450579],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743774,0.007840904,0.001115052,0.001981015,0.001124354,0.003666425,0.00386919,0.0005347022,0.005491045],"genre_scores_gemma":[0.970619,0.00389293,0.002805828,0.002726047,0.0006724906,0.004620217,0.005428264,0.0001161546,0.00911906],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01021677,"threshold_uncertainty_score":0.0341785,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09570365100150162,"score_gpt":0.4280696711511847,"score_spread":0.332366020149683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}